Delving into the Latest Updates on Talquetamab with Synapse

Overview

Basic Info

Drug Type

Bispecific T-cell Engager (BiTE)

Synonyms

DuoBody, TALQUETAMAB-TGVS, 替吉妥单抗

+ [7]

Target

CD3 x GPRC5D

Action

stimulants, inhibitors

Mechanism

CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Refractory Multiple MyelomaRelapse multiple myelomaMultiple Myeloma+ [5]

Inactive Indication-

Originator Organization

Janssen Pharmaceuticals, Inc.

Active Organization

Janssen Biotech, Inc.

Janssen Pharmaceutica NV

Johnson & Johnson

+ [8]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (09 Aug 2023),

Multiple Myeloma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Conditional marketing approval (European Union)

Login to view timeline

Structure/Sequence

Sequence Code 10086313H

Source: *****

Sequence Code 10086327L

Source: *****

Sequence Code 453116282H

Source: *****

Sequence Code 525754800L

Source: *****

BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions.
New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.

Start Date01 Mar 2027

Sponsor / Collaborator

Rigshospitalet

NCT07029776

/ Not yet recruitingPhase 2

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)

The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.

Start Date01 Jul 2026

Sponsor / Collaborator

Janssen Research & Development LLC

NCT07499323

/ Not yet recruitingNot ApplicableIIT

A Preliminary Case Study to Evaluate the Efficacy and Safety of Talquetamab in Patients With Refractory Generalized Myasthenia Gravis

Myasthenia Gravis (MG) is a chronic autoimmune disease mediated by pathogenic antibodies. Approximately 10%-15% of patients present with refractory status, defined as having an inadequate response to existing therapies or an inability to tolerate the side effects of the medication, highlighting an urgent need for the development of more targeted innovative therapies. Talquetamab is a bispecific antibody that targets G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and the Cluster of Differentiation 3 (CD3) molecule on the surface of T cells, thereby inducing T cells to precisely eliminate GPRC5D-positive cells. This study will conduct an exploratory case series to investigate the efficacy and safety of Talquetamab in refractory MG.

Start Date20 Mar 2026

Sponsor / Collaborator

Chongqing Medical University /The First Affiliated Hospital/

100 Clinical Results associated with Talquetamab

Login to view more data

100 Translational Medicine associated with Talquetamab

Login to view more data

100 Patents (Medical) associated with Talquetamab

Login to view more data

124

Literatures (Medical) associated with Talquetamab

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care

Article

Author: Mu, Fan ; Patel, Neel ; Yang, Chelsey ; Jiao, Tianze ; Liu, Yi-Hsuan ; Grajales-Cruz, Ariel F. ; Wang, Jiamin ; Lee, Hans C. ; Zhang, Xinke ; Goble, Joseph

AIMS:

To evaluate costs per responder for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM) receiving talquetamab (Tal) on weekly (QW) and biweekly (Q2W) dosing schedules, compared with usual care from a United States commercial payer's perspective.

METHODS:

A cost per responder model was developed over a 6-month time horizon, incorporating pre-progression and post-progression costs. For Tal QW and Tal Q2W, pre-progression costs included costs of drug acquisition, inpatient step-up doses (hospitalization, pre-medication, and tocilizumab), outpatient visits, and monitoring. Pre-progression costs for usual care were estimated based on a weighted average of the 10 most used regimens in a real-world LocoMMotion/MoMMent study, including costs of acquisition, administration, co-medication, and monitoring. Post-progression costs included subsequent treatment for a subset of patients and terminal care costs prior to death. All costs were reported in 2025 United States Dollars. Clinical data of overall response rate (ORR), progression-free survival, and overall survival were obtained from an indirect treatment comparison using MonumenTAL-1 (September 2024 data cut) and LocoMMotion/MoMMent (October 2022 and August 2023 data cuts) as data sources. Deterministic sensitivity analyses and scenario analyses were conducted to assess the robustness of model results.

RESULTS:

Over the 6-month period, the total cost of care was $179,556 for usual care, $295,993 for Tal QW, and $315,135 for Tal Q2W. Despite higher costs, Tal demonstrated superior ORR, resulting in lower cost per responder: $575,962 for usual care, $405,470 for Tal QW, and $443,165 for Tal Q2W, representing a 23-30% reduction in cost per responder with Tal. Sensitivity and scenario analyses showed consistent findings.

CONCLUSION:

Although Tal QW and Q2W are associated with higher total per-patient costs compared with usual care, they offer improved clinical effectiveness, resulting in lower cost per responder. These findings suggest greater economic value for Tal in the treatment of TCE RRMM.

26 Mar 2026·CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Extended verification of an automated MALDI-TOF mass spectrometry system for high throughput serum M-protein measurement

Article

Author: Langlois, Michel R. ; Van Hecke, Emile ; Nevejan, Louis ; Schauwvlieghe, Alexander ; Bossuyt, Xavier ; Van Droogenbroeck, Jan ; Vercammen, Martine

Abstract:

Objectives:

This study aimed to perform an extended analytical verification of the Immunoglobulin Isotypes (GAM) for the EXENT ® Analyzer (EXENT ® -GAM) assay, a MALDI-TOF mass spectrometry-based method for detecting and quantifying serum M-proteins in patients with plasma cell dyscrasias, and to compare it with conventional serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (sIFE) and serum free light chains (sFLC) assays.

Methods:

Imprecision, linearity, limit of quantification (LOQ), quantification comparison with SPEP, isotyping concordance with sIFE and sFLC, interference from therapeutic monoclonal antibodies (t-mAbs), sample stability, and reagent lot consistency were evaluated.

Results:

EXENT ® -GAM demonstrated acceptable imprecision (CV ≤20 % for low and ≤15 % for high M-protein levels) and wide linear range (∼0.03–30 g/L). The polyclonal immunoglobulin background negatively influenced the assays LOQ. M-proteins with mass-shifted light chains (i.e., glycosylated light chains) are prone to non-linearity and inferior LOQ. M-protein quantification by EXENT ® differed systematically and proportionally from quantification by SPEP, highlighting non-interchangeability. EXENT ® demonstrated 97 % concordance with sIFE for M-protein isotyping and identified numerous additional (low-level) M-proteins. Some proved to be clinically relevant (residual disease in sIFE-negative samples); others lacked correlation with sFLC result or clinical diagnosis. EXENT ® reliably distinguished endogenous M-proteins from t-mAbs, except talquetamab, which interfered with quantification and was partially misclassified.

Conclusions:

EXENT ® -GAM enables sensitive and reproducible quantification and isotyping of M-proteins below the detection limit of SPEP and sIFE. Its ability to resolve analytical challenges posed by SPEP and sIFE represents a significant advancement. Further clinical studies are needed to confirm its potential in residual disease detection.

01 Mar 2026·Transplantation and Cellular Therapy

Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study

Article

Author: Irfan, Sohaib ; Kamboj, Ishita ; Rahman, Raeef ; Qureshi, Raabia ; Ahmed, Nausheen ; Abdallah, Al-Ola ; Ayoobkhan, Fathima Shehnaz ; Lutfi, Forat ; Mahmoudjafari, Zahra ; McGuirk, Joseph ; Vojjala, Nikhil

Chimeric antigen receptor T-cell therapy (CAR-T) and T-cell engager antibody (TCE) revolutionized relapsed refractory multiple myeloma (RRMM), non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL) treatment. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a potentially fatal rare complication characterized by cytopenia, coagulopathy, transaminasemia, and hyperferritinemia. We aim to analyze the IEC-HS reported cases, patterns, and outcomes in RRMM and NHL patients undergoing CAR-T and TCE therapy utilizing the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. We conducted a retrospective postmarketing pharmacovigilance inquiry using the FAERS database and the Medical Dictionary for Regulatory Activities (MEDRA). The database was accessed on March 20, 2025 to examine the adverse effects of CAR-T: idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel), and TCE (teclistamab, elranatamab, talquetamab, mosunetuzumab, glofitamab, and epcoritamab) since their FDA approval in the United States and non-US populations. Descriptive analysis was used to describe reported proportions and outcomes. Reported mortality per product was calculated for patients with IEC-HS. Cases reported in 2024, were used to calculate reporting odds ratio (ROR) and empirical Bayesian geometric mean (EBGM) to compare the drugs for IECHS events reported. A total of 23,315 unique case safety reports (ICSRs) were analyzed, identifying 378 (1.62%) reports of IEC-HS. Reported mortality was high among these patients (n = 232/378, 61.3%). A formal disproportionality analysis, limited to 2024 reports to ensure a contemporary comparison, was performed. Tisa-cel (ROR 2.20) and cilta-cel (ROR 2.24) both demonstrated statistically significant disproportionate reporting signals for IEC-HS. In contrast, axi-cel, which accounted for the highest absolute number of reports (n = 114/378), did not show a significant signal in this analysis (ROR 1.02), suggesting its high case volume is proportional to its high overall reporting frequency. Teclistamab showed a significantly reduced likelihood of HLH reporting (ROR 0.43). IEC-HS is a rare but potentially fatal complication. Our disproportionality analysis identifies significant reporting signals for tisa-cel and cilta-cel. The high absolute number of cases observed for products like axi-cel appears to reflect high utilization rather than a disproportionate risk, underscoring the necessity of using statistical signal detection methods when interpreting spontaneous reports.

143

News (Medical) associated with Talquetamab

14 Apr 2026

·firstwordpharma.com

As Stelara fades, J&J touts early momentum for new psoriasis pill Icotyde

Johnson & Johnson said its newly launched oral IL-23 peptide Icotyde (icotrokinra) has already racked up roughly 1500 prescriptions in the first few weeks since its March approval for plaque psoriasis, a pace that has company executives abuzz about the drug's prospects."It's off to a very fast start," said Jennifer Taubert, EVP for Innovative Medicine, at J&J's first-quarter earnings call Tuesday. "We think it's got the potential to become one of our biggest products."The once-daily pill is indicated for moderate-to-severe psoriasis patients as young as 12 years old who are candidates for systemic therapy or phototherapy. In head-to-head superiority studies, Icotyde showed superior skin clearance when put up against Bristol Myers Squibb's oral TYK2 inhibitor Sotyktu (deucravacitinib), while having a safety profile akin to placebo.'One-two punch'"A number of us were out at the AAD (American Academy of Dermatology) meeting as well, and the KOL receptivity to the strength and the simplicity of the label has been really encouraging," Taubert said. "Things like no lab monitoring…no black box or drug interactions really is giving us good confidence that this is going to be really the preferred choice in first choice for systemic therapy." FirstWord is running a poll to gauge early physician expectations for the drug, click here to be notified of the results.Icotyde's role was also highlighted alongside Tremfya (guselkumab), J&J's established injectable biologic for psoriasis, which the company predicts will exceed $10 billion in peak annual sales. Tremfya, which treats psoriasis as well as inflammatory bowel diseases (IBD), generated $1.6 billion in first-quarter sales, up 68% year-over-year, and beat estimates of $1.2 billion."We think that with that one-two punch, we have got the portfolio for psoriatic disease and patients that are really excited about both agents going forward," Taubert said, adding "we're in the middle of very, very positive conversations with [payors] to try to drive…early and very broad access."Data for Icotyde in psoriatic arthritis is expected to read out later this year; the drug is currently being evaluated in the Phase III ICONIC-PsA 1 and ICONIC-PsA 2 studies. Enrollment is also underway in a pair of IBD trials; ICONIC-UC in ulcerative colitis and ICONIC-CD in Crohn's disease.Moving beyond StelaraMeanwhile, the performance of J&J's former blockbuster Stelara – used to treat psoriasis, Crohn’s disease and other autoimmune conditions – continues its downward slide in the face of biosimilar competition, with quarterly sales tumbling nearly 60% during the quarter to $656 million (see – Vital Signs: Fastest falling drugs of 2025).However, instead of switching to biosimilars, Chief Financial Officer Joseph Wolk told CNBC, "We are seeing increased share in Tremfya and we anticipate we'll see something similar in the new oral offering."In other results, J&J reported that sales of its multiple myeloma treatment Darzalex were 22.5% higher in the quarter at $4 billion, compared to the year-ago period, whereas analysts were projecting $3.4 billion. Newer blood cancer therapies Carvykti ($597 million, +62.1%), Tecvayli ($202 million, +33.5%) and Talvey ($152 million, 76.7%) also helped drive growth."[J&J] has emerged as one of the cleaner names in the group as the company moves beyond the Stelara loss of exclusivity and with healthy growth in its core portfolio," said JP Morgan analysts. "We see J&J as capable of generating sustained top-tier growth."The company bumped up its full-year sales forecast to between $100.3 billion and $101.3 billion, nudging both ends of the previous range up by $300 million. Profit is expected to be higher as well, with earnings now estimated to be between $11.45 and $11.65 per share, a two-cent bump at each end of the range.

14 Apr 2026

·www.biopharmadive.com

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

Dive Brief:Johnson & Johnsons first-quarter results beat Wall Streets expectations, as its innovative medicines division posted sales of just over $15 billion, an 11% increase over the same period in 2025.Overall company sales rose just shy of 10%, too, though net profit plummeted by more than half, to just over $5 billion.J&J delivered that strong growth amid plummeting numbers for the autoimmune drug Stelara, which was once its biggest product but began facing biosimilar competition last year. The companys newer autoimmune medication Tremfya, as well as its oncology portfolio, are helping offset those losses, posting 74% and 20% sales growth, respectively.The first-quarter results also led J&J to slightly hike its 2026 guidance from Januarys forecast. It now expects total annual sales to edge over $100 billion and per-share earnings to come in between $11.45 and $11.65.Dive Insight:Stelara, as recently as 2024, was J&Js most lucrative drug, with more than $10 billion in sales that constituted nearly 12% of the companys overall revenue. But J&J has found an able successor in Tremfya, which works similarly to Tremfya and, since its 2017 launch, has been cleared to treat most of the same immunological conditions.The newer drug has yet to completely offset Stelaras decline; J&Js immunology drugs fell nearly 9% in the first quarter compared to the same period last year. Still, Tremfya is poised to become a bigger seller, as clearances over the last few years in Crohns disease and ulcerative colitis helped it reach $1.6 billion in the first quarter alone, RBC Capital Markets analyst Shagun Singh wrote in a client note.J&Js oncology portfolio particularly its four-drug franchise of multiple myeloma treatments has proven a steadier counterweight to Stelaras losses. Darzalex alone posted nearly $4 billion in first-quarter sales, and the overall business, which includes the cell therapy Carvykti and the bispecific antibodies Tecvayli and Talvey,added about $5 billion to J&Js top line. Darzalexs main U.S. patents are due to expire in 2029, though, so J&J will need new or existing products to help absorb that upcoming loss.In the meantime, though, J&J executives said they believe the company is on track to achieve double-digit sales growth for the entire company, including its medical devices business, by the end of the decade. Expanded use of multiple myeloma drugs and a newly launched psoriasis pill called Icotyde are among the drivers of future growth, they said. '

Drug ApprovalFinancial StatementBiosimilarPatent Expiration

31 Mar 2026

·www.einpresswire.com

October - December 2025 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event Monitoring System (AEMS)

Alyglo (immune globulin intravenous, human-stwk) Increased hypersensitivity reactions in patients receiving certain product lots FDA is evaluating the need for regulatory action. Bispecific T-cell engager therapies Columvi (glofitamab-gxbm) injection Epkinly (epcoritamab-bysp) injection Imdelltra (tarlatamab-dlle) for injection Kimmtrak (tebentafusp-tebn) injection Talvey (talquetamab-tgvs) injection Hypogammaglobulinemia FDA is evaluating the need for regulatory action. Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Mavenclad (cladribine) tablets Colitis FDA is evaluating the need for regulatory action. Calquence (acalabrutinib) capsules; tablets Aplastic anemia FDA is evaluating the need for regulatory action. Datroway (datopotamab deruxtecan-dlnk) for injection Infusion related reaction, including anaphylaxis FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Hepatitis B reactivation FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Rhabdomyolysis FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Tuberculosis FDA is evaluating the need for regulatory action. Metformin-containing products Lactic acidosis in patients with mitochondrial disease FDA is evaluating the need for regulatory action. Vecuronium bromide injection (a particular generic product) Product label confusion The peel-off sticker on the container label was revised to include all required information, including the total quantity of drug substance per total volume and the expression of strength as 1 mg/mL concentration after reconstitution. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

100 Deals associated with Talquetamab

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Refractory Multiple Myeloma	Japan	Janssen Pharmaceutical KK	24 Jun 2025
Relapse multiple myeloma	Japan	Janssen Pharmaceutical KK	24 Jun 2025
Multiple Myeloma	United States	Janssen Biotech, Inc.	09 Aug 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Extramedullary Disease in Multiple Myeloma	Phase 2	United States	Janssen Research & Development LLC	01 Jul 2026
Residual Neoplasm	Phase 2	United States	Johnson & Johnson	21 Aug 2025
Peripheral Stem Cell Transplantation	Phase 2	United States	Janssen Scientific Affairs LLC	05 Jun 2025
Smoldering Multiple Myeloma	Phase 2	United States	Janssen Scientific Affairs LLC	04 Dec 2023
Hematologic Neoplasms	Phase 1	United States	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Belgium	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Netherlands	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Spain	Janssen Research & Development LLC	16 Dec 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Refractory Multiple Myeloma	43	Teclistamab	ygdfmihrpi(fofzvegkuk) = tjtblemqxs gfzvkbubez (xbnbuhgpqs )	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Refractory Multiple Myeloma	43	Elranatamab	ygdfmihrpi(fofzvegkuk) = evgoctgybm gfzvkbubez (xbnbuhgpqs )	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Multiple Myeloma	465	Teclistamab	pjytnoises(ohkubsjtrj) = svbjqjjwsg bjdtyhuzhm (vgyhnxnhqo ) View more	Negative	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Multiple Myeloma	465	Elranatamab	pjytnoises(ohkubsjtrj) = wafoiuodom bjdtyhuzhm (vgyhnxnhqo ) View more	Negative	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Relapse multiple myeloma \| Renal Insufficiency	36	Talquetamab (Renal Impairment)	ajzffqnuwg(ncvtmedvpo) = Comparable safety profile in RI vs No RI: 66.7% any-grade cytokine release syndrome (CRS) with 8.3% grade ≥3 CRS in each, but more grade 1 CRS in RI 58.3% vs 45.8% (=0.73). Any-grade Immune effector cell-associated neurotoxicity syndrome (ICANS) was 16.7% vs 20.8%, with grade ≥3 ICANS 8.3% vs 12.5%. Infection rate 8.3% vs 16.7% (=0.65), dysgeusia was 83.3% in each, skin-related AEs 75% vs 58.3% (=0.47), and nail-related AEs 83.3% vs 54.2% (=0.14). Median inpatient step-up dosing was 10 vs 9 days (=0.23). ivvojsnxui (fqmmtgxvlg ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Relapse multiple myeloma \| Renal Insufficiency	36	Talquetamab (No Renal Impairment)		Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Relapse multiple myeloma	25	Talquetamab	prjhbeuije(rldjavvcwz) = rqjjzzkewh xmuuuhnhig (ffjeztmgyf ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Solid tumor \| Hematologic Neoplasms	61	Bispecific Therapies	nsujzhdpbx(gycyavitjc) = lrtyjhbrbd yivqjeedvq (jcuwrtxsda ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Hematologic Neoplasms	10	CAR-T	qebedbgovo(uamlkshaxy) = mastiufgsv jtieqjpxzh (vaplcycbjw ) View more	Positive	04 Feb 2026
NCT04586426 (RedirecTT-1, Pubmed \| N Engl J Med)	Phase 2	Multiple Myeloma	90	Talquetamab plus Teclistamab	splgqfqius(ogabfcglgn) = ujekjayjiw uqeojwwokj (wagrebwcdn, 69 - 87) View more	Positive	01 Jan 2026
NCT04586426 (RedirecTT-1, Pubmed \| N Engl J Med)	Phase 2	Multiple Myeloma	90	Talquetamab plus Teclistamab	wqkwrswfpj(gyqcqmiuep) = ebwduplxbq ftbuzfkxdx (brbecbfnjx, 69 - 87) View more	Positive	07 Dec 2025
ASH2025	Not Applicable	Relapse multiple myeloma	484	Talquetamab	xvlsivgzbd(bthpoocdom) = gxbpfwawqo vahcwhqvfe (uslqoptcen ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Multiple Myeloma	16	Talquetamab or Elranatamab with Pomalidomide combinations	ppdxdhyasd(rmaheoxpoq) = goytvjijff krxwguxtik (seuziqiuvg ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Multiple Myeloma	16	Talquetamab or Elranatamab with Pomalidomide combinations	gwultceixm(hkauhrvsvz) = zrljrlslxm dglotlhwes (yvrfrkclkt )	Positive	06 Dec 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data